Business Wire

PANASONIC/KOSE

6.12.2019 03:39:11 CET | Business Wire | Press release

Share
Panasonic and KOSÉ Set to Commence Verification Test for Personalized Proposals Utilizing Snow Beauty Mirror

Panasonic Corporation is collaborating with KOSÉ Corporation to conduct a joint verification test using Snow Beauty Mirror, a system under development by Panasonic, with the aim of offering personalized proposals at Maison KOSÉ, a store which is due to open on December 17. Through this initiative, Panasonic will help make new personalized proposals that meet the diverse needs of its customers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191205005971/en/

People’s values and lifestyles are becoming increasingly diverse. In today’s world, everyone requires something different from their cosmetics. Meanwhile, customers are confronted with a deluge of information through the Internet and social media, which sometimes makes it difficult for them to select cosmetics that really suit their needs. A solution to this conundrum is personalized proposals which utilize digital technologies and data to introduce individuals to the optimal products and services.

Maison KOSÉ is a new type of concept store, a place where people will be able to come and experience these personalized proposals firsthand using Snow Beauty Mirror. Visitors will also be able to try out Customized Sheets (provisional name), which adopts the Make-up Sheet technology currently under development at Panasonic.

Functions of Snow Beauty Mirror and content of verification test

1. Skin analysis

All customers need to do is sit in front of the mirror. The system then analyzes the customer’s skin profile and displays numerical data instantly on the mirror. Contactless sensors embedded in the mirror detect the condition of both the skin’s surface and below the surface. With a degree of precision on par with medical devices, the system detects not only spots, wrinkles, smile lines, pores and skin tone, but also hidden spots otherwise invisible to the naked eye. Then, based on digital counselling and analysis results, the system recommends the optimal package for each individual customer from among KOSÉ’s products and services spanning multiple brands*1 . This function utilizes facial recognition and image processing technologies used in digital cameras, et al.

2. Ideal face image system

Combining genetic algorithms, developed as a joint venture between KOSÉ and Meiji University, with Panasonic’s image processing technologies has enabled the creation of a system which makes it possible to visualize a person’s “ideal face” from facial image data—that is, how the customer would really like to appear. Snow Beauty Mirror’s high-precision skin analysis function detects the customer’s skin conditions in terms of pores, spots and wrinkles, as well as the skin’s tones and brightness, and adjusts the parameters of this data to create around 500,000 facial image patterns. The customer selects their preferred facial image from among randomly displayed facial images, generating their ideal face in a short time. The system can visualize the differences between the customer’s ideal face and current appearance, while providing tips on the perfect foundation tone, texture and application techniques to help them get closer to their ideal face.

3. Customized Sheets which apply Make-up Sheet technology

Currently under development at Panasonic, Make-up Sheets are ultra-thin*2 cosmetic sheets printed with tones that perfectly match the customer’s skin. They combine skin analysis data from Snow Beauty Mirror, and the company’s proprietary printing technology. Customers simply need to stick the sheets over areas of concern on their cheeks or temples.

In this verification test, Panasonic will combine its Make-up Sheet technology, proprietary skin tone analysis technology, and printing technology with KOSÉ’s extensive knowledge of cosmetic development. The aim is to create Customized Sheets (provisional name) that achieve a natural color match and an ideal fit with the customer’s skin.


Panasonic will continue to fuse its cutting-edge technologies with KOSÉ’s development capabilities in cosmetics to expand the scope of Snow Beauty Mirror, pursuing possibilities that go beyond the field of beauty treatment. In this way, the company will meet the diverse needs of its customers and better contribute to society through improved QOL.

Notes:
*1. KOSÉ Group’s skin care brands, excluding ALBION
*2. Thickness of 100 nanometers (one nanometer = one billionth of a meter)

About Maison KOSÉ

A fun concept store stocking and linking all KOSÉ brands*3 , providing customers with an early chance to try a range of new software and hardware relating to cosmetics and beauty treatment. The store facilitates new forms of communication which fuse digital and experiential approaches, exploring new possibilities for the next generation of cosmetic experiences and working to connect customers digitally to the store. It also serves as a place of communication with customers, functioning as a seat of learning where information and experiences can be quickly fed back into the company.

*3 Excluding some products

About Panasonic

Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 582 subsidiaries and 87 associated companies worldwide, recording consolidated net sales of 8.003 trillion yen for the year ended March 31, 2019. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: https://www.panasonic.com/global .

Source: https://news.panasonic.com/global/press/data/2019/12/en191206-2/en191206-2.html

Related Links

[Video] Make-up Sheet / Technology & Innovation of Panasonic
https://channel.panasonic.com/contents/25818/

[Video] Solving skin concerns with innovation using the “Make-up Sheet” [Panasonic]
https://channel.panasonic.com/contents/25819/

Brand Story | Panasonic
https://www.panasonic.com/global/corporate/brand/story.html

Panasonic R&D Overview | Panasonic
https://www.panasonic.com/global/corporate/technology-design/r-and-d.html

Breakthrough Technology | Panasonic
https://www.panasonic.com/global/corporate/technology-design/technology.html

KOSÉ Corporation
https://www.kose.co.jp/global/en/

Link:

ClickThru

Social Media:

https://www.facebook.com/PanasonicCorporation

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye